Putting ACCOMPLISH into context: Management of hypertension in 2010

CMAJ. Canadian Medical Association Journal

Volumn 182, Issue 15, 2010, Pages 1600-1601

  McAlister, Finlay A ^a   Herman, Robert J ^b   Khan, Nadia A ^c   Rabkin, Simon W ^c   Campbell, Norm ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b LIBIN CARDIOVASCULAR INSTITUTE OF ALBERTA   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE; THIAZIDE DIURETIC AGENT; ANTIHYPERTENSIVE AGENT;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; HIGH RISK PATIENT; HUMAN; HYPERTENSION; NOTE; PROGNOSIS; CARDIOVASCULAR DISEASES; DRUG COMBINATION; MIDDLE AGED; PRACTICE GUIDELINE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR DISEASES; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; SODIUM CHLORIDE SYMPORTER INHIBITORS;

EID: 78049247033     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.092142     Document Type: Note

References (13)

1. Jamerson K, Weber MA, Bakris GL, et al.; ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorthiazide for hypertension in high-risk patients. N Engl J Med 2008;359:2417-28.
2. Zanchetti A, Mancia G, Black HR, et al. Facts and fallacies of blood pressure control in recent trials: implications in the management of patients with hypertension. J Hypertens 2009;27:673-9.
3. Chobanian AV. Does it matter how hypertension is controlled? N Engl J Med 2008;359: 2485-8.
4. Bakris GL, Sarafidis PA, Weir MR, et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010;375:1173-81.
5. McAlister FA, Sackett DL. Active-control equivalence trials and antihypertensive agents. Am J Med 2001;111:553-8.
6. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomized controlled trial. Lancet 2007;370:829-40.
7. Montori VM, Devereaux PJ, Adhikari NK, et al. Randomized trials stopped early for benefit: a systematic review. JAMA 2005;294:2203-9.
8. Heerspink HL, de Zeeuw D. Composite renal endpoints: Was ACCOMPLISH accomplished? Lancet 2010;375:1140-2.
9. ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97.
10. Weber MA, Julius W, Kjeldsen SE, et al. Blood pressure dependent and independ - ent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004;363:2049-51.
11. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009;338:b1665. doi: 10.1136/bmj.b1665.
12. Ioannidis JP. Contradicted and initially stronger effects in highly cited clinical research. JAMA 2005;294:218-28.
13. Lawes CMM, Vander Hoorn S, Law MR, et al. Blood pressure and the global burden of disease 2000. Part II: Estimates of attributable burden. J Hypertens 2006;24:423-30.